Systematic review and meta-analysis: Anti-tumor necrosis factor α therapy and cardiovascular events in rheumatoid arthritis
Published 2010 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Systematic review and meta-analysis: Anti-tumor necrosis factor α therapy and cardiovascular events in rheumatoid arthritis
Authors
Keywords
-
Journal
ARTHRITIS CARE & RESEARCH
Volume 63, Issue 4, Pages 522-529
Publisher
Wiley
Online
2010-10-19
DOI
10.1002/acr.20371
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
- (2013) David Moher ANNALS OF INTERNAL MEDICINE
- EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis
- (2009) M J L Peters et al. ANNALS OF THE RHEUMATIC DISEASES
- Improvement of lipid profile is accompanied by atheroprotective alterations in high-density lipoprotein composition upon tumor necrosis factor blockade: A prospective cohort study in ankylosing spondylitis
- (2009) I. C. van Eijk et al. ARTHRITIS AND RHEUMATISM
- Does TNF-alpha blockade play any role in cardiovascular risk among rheumatoid arthritis (RA) patients?
- (2009) Raquel Cuchacovich et al. CLINICAL RHEUMATOLOGY
- The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review
- (2009) S. L. Westlake et al. RHEUMATOLOGY
- Trends in cardiovascular mortality in patients with rheumatoid arthritis over 50 years: a systematic review and meta-analysis of cohort studies
- (2009) C. Meune et al. RHEUMATOLOGY
- Tumor necrosis factor-α antagonist use and heart failure in elderly patients with rheumatoid arthritis
- (2008) Soko Setoguchi et al. AMERICAN HEART JOURNAL
- Mortality Reduction with Influenza Vaccine in Patients with Pneumonia Outside “Flu” Season
- (2008) Dean T. Eurich et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: Findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study
- (2008) Edward Keystone et al. ARTHRITIS AND RHEUMATISM
- Short-term improvement of endothelial function in rituximab-treated rheumatoid arthritis patients refractory to tumor necrosis factor α blocker therapy
- (2008) Carlos Gonzalez-Juanatey et al. ARTHRITIS AND RHEUMATISM
- Does tumor necrosis factor α inhibition promote or prevent heart failure in patients with rheumatoid arthritis?
- (2008) Joachim Listing et al. ARTHRITIS AND RHEUMATISM
- Risk of cardiovascular mortality in patients with rheumatoid arthritis: A meta-analysis of observational studies
- (2008) J. Antonio Aviña-Zubieta et al. ARTHRITIS AND RHEUMATISM
- Impact of Traditional Therapies and Biologics on Cardiovascular Diseases in Rheumatoid Arthritis
- (2008) Jean-Frederic Boyer et al. Current Vascular Pharmacology
- Cardiovascular risk in rheumatoid arthritis: effects of anti-TNF drugs
- (2008) J Avouac et al. EXPERT OPINION ON PHARMACOTHERAPY
- Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial
- (2008) Paul Emery et al. LANCET
- Sustained improvement of vascular endothelial function during anti‐TNFα treatment in rheumatoid arthritis patients
- (2008) P. I. Sidiropoulos et al. SCANDINAVIAN JOURNAL OF RHEUMATOLOGY
- Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study
- (2008) Antonio Naranjo et al. ARTHRITIS RESEARCH & THERAPY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started